针对粉样β介导的阿尔茨海默氏症病理生理学中的表观遗传机制:揭示治疗潜力
Jennie Z Li1, Nagendran Ramalingam, Shaomin Li
1Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Neural regeneration research
|May 20, 2024
概括
表观遗传修饰,包括DNA甲基化和基因素变化,在阿尔茨海默病 (AD) 和突触可塑性中至关重要. 量身定制的表观遗传药物可能为AD提供新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,与粉样β寡合体和突触功能障碍有关.
- 环境因素诱导表观遗传修饰,影响基因表达,突触形成和可塑性.
研究的目的:
- 审查表观遗传机制 (DNA甲基化,基因组修饰,微RNAs) 在AD病变发生过程中的作用.
- 探索针对AD的突触功能和可塑性的治疗策略.
主要方法:
- 关于阿尔茨海默病表观遗传机制的文献综述.
- 分析环境因素及其对基因表达和突触可塑性的影响.
- 探索治疗干预措施,包括丰富的环境,大脑刺激和药物干预剂.
主要成果:
- 表观遗传因素是突触功能和活动依赖可塑性的组成部分.
- 丰富环境和非侵入性脑刺激等策略显示出改善突触功能的潜力.
- 长期的强化与表观遗传机制密切相关.
结论:
- 表观遗传修饰在阿尔茨海默病的发展和进展中起着重要作用.
- 针对性表观遗传疗法,对于不同的疾病阶段可能是不同的,对阿尔茨海默病的治疗有希望.
- 为了有效治疗阿尔茨海默病,需要采用多方面的方法,可能涉及定制表观遗传药物.
相关概念视频
01:22Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
01:26Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465